REGULATED INFORMATION March 12, 2013 TiGenix Reports Full Year 2012 Financial Results * ChondroCelect sales increase to EUR 4.1 million, up 101% * Cx611 RA program reported positive interim safety results * Cx601 ADMIRE-CD trial ongoing in 8 countries * EUR 11.1 million cash at December 31, 2012 Leuven - March 12, 2013 -TiGenix NV , the European ... (more)
More...
More...